

Mycoplasma Testing Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Product (Instruments, Kits and Reagents), By Technology (PCR, ELISA, Enzymatic Methods, DNA Staining, Other), By Application (Cell Line Testing, Bioproduction Testing, Other), By End-User (Academic Research Institutes, Cell Banks, Contract Research Organizations, Pharmaceutical & Biotechnology Companies, Others), By Region, Competition, 2020-2030F

https://marketpublishers.com/r/M3271BF1897DEN.html

Date: March 2025

Pages: 185

Price: US\$ 4,500.00 (Single User License)

ID: M3271BF1897DEN

Abstracts

Global Mycoplasma Testing Market was valued at USD 1090.70 Million in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 13.45% through 2030. The Global Mycoplasma Testing Market is a dynamic and rapidly evolving sector within the broader field of diagnostics and infectious disease management. Mycoplasma, a genus of bacteria known for their lack of a cell wall, can infect various host organisms, including humans, animals, and cell cultures. Mycoplasma contamination poses a significant threat to research, biopharmaceutical manufacturing, and clinical diagnostics, making mycoplasma testing an essential component of quality control and safety assurance.

Key Market Drivers

Rising Biopharmaceutical and Biotechnology Industries



The rapid expansion of the biopharmaceutical and biotechnology industries is a key driver of the Global Mycoplasma Testing Market. Over the past few years, the number of FDA-registered manufacturing facilities in the U.S. producing human-use medicines, along with their associated testing, labeling, and packaging operations, has surged by more than 50%. Biopharmaceutical companies are actively investing in new construction, facility expansions, and technology upgrades to support the production of next-generation therapies, ensuring a robust and scalable supply chain for advanced treatments across the country. These industries rely heavily on cell culture-based production processes, where contamination can compromise product integrity, regulatory compliance, and patient safety. Mycoplasma, a frequent and insidious contaminant, necessitates stringent testing protocols to ensure the purity and efficacy of biopharmaceutical products. The rising investments, increasing adoption of biologics, and growing need for quality control in biotech processes directly fuel the demand for mycoplasma testing. Biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and biosimilars, are revolutionizing modern medicine. These products rely on mammalian cell cultures for production, making them highly susceptible to mycoplasma contamination. The growing adoption of biologics for treating chronic diseases, including cancer, autoimmune disorders, and infectious diseases, necessitates stringent contamination control measures. As patents for biologic drugs expire, biosimilar manufacturers must comply with regulatory guidelines for mycoplasma testing to ensure their products meet the same safety and efficacy standards as originator biologics. With global sales of biologics projected to surpass traditional pharmaceuticals, mycoplasma testing has become an integral part of quality assurance in drug development and production.

Key Market Challenges

Cost Constraints in Developing Regions

One of the significant challenges in expanding the mycoplasma testing market is the cost associated with acquiring and implementing testing solutions. In developing regions with limited healthcare budgets, investing in expensive mycoplasma testing equipment and reagents can be prohibitive.

Many developing countries allocate a substantial portion of their healthcare budgets to basic healthcare needs like vaccinations and infectious disease control. This leaves limited resources for advanced diagnostic technologies, including mycoplasma testing. Establishing a mycoplasma testing infrastructure, including purchasing specialized equipment and training personnel, requires a considerable initial investment that some



regions may struggle to afford. Continuous testing relies on a steady supply of costly reagents and consumables, which can be a financial burden for healthcare facilities in resource-constrained areas.

Key Market Trends

Rapid Adoption of Molecular Diagnostics

One significant trend in the Global Mycoplasma Testing Market is the rapid adoption of molecular diagnostics, particularly Polymerase Chain Reaction (PCR)-based methods.

Molecular diagnostic techniques, such as PCR, offer unparalleled sensitivity and specificity in detecting mycoplasma DNA. They can identify even low levels of contamination quickly and accurately. Molecular tests provide rapid results, often within hours, compared to traditional culture-based methods that can take days or even weeks. This speed is crucial in maintaining the efficiency of biopharmaceutical production and research. Automated molecular testing platforms allow for high throughput, making them suitable for large-scale testing in biopharmaceutical manufacturing facilities. PCR-based methods reduce the risk of false positives associated with traditional culture-based techniques, as they do not rely on the growth of mycoplasma cells.

Key Market Players

Agilent Technologies Inc

ATCC

Bionique Testing Laboratories Inc.

Charles River Laboratories International Inc.


Lonza Group Ltd

Merck KGaA

Bionique Testing Laboratories Inc.

PromoCell GmbH







Academic Research Institutes
Cell Banks
Contract Research Organizations
Pharmaceutical & Biotechnology Companies
Others
Mycoplasma Testing Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India



Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Mycoplasma Testing Market.
Available Customizations:
Global Mycoplasma Testing market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information

Detailed analysis and profiling of additional market players (up to five).



Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. MYCOPLASMA TESTING MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Product (Instruments, Kits and Reagents)
 - 5.2.2. By Technology (PCR, ELISA, Enzymatic Methods, DNA Staining, Other)
 - 5.2.3. By Application (Cell Line Testing, Bioproduction Testing, Other)
- 5.2.4. By End-User (Academic Research Institutes, Cell Banks, Contract Research



Organizations, Pharmaceutical & Biotechnology Companies, Others)

- 5.2.5. By Region
- 5.2.6. By Company (2024)
- 5.3. Market Map

6. NORTH AMERICA MYCOPLASMA TESTING MARKET OUTLOOK

- 6.1. Market Size & Forecast
 - 6.1.1. By Value
- 6.2. Market Share & Forecast
 - 6.2.1. By Product
 - 6.2.2. By Technology
 - 6.2.3. By Application
 - 6.2.4. By End User
 - 6.2.5. By Country
- 6.3. North America: Country Analysis
 - 6.3.1. United States Mycoplasma Testing Market Outlook
 - 6.3.1.1. Market Size & Forecast
 - 6.3.1.1.1. By Value
 - 6.3.1.2. Market Share & Forecast
 - 6.3.1.2.1. By Product
 - 6.3.1.2.2. By Technology
 - 6.3.1.2.3. By Application
 - 6.3.1.2.4. By End User
 - 6.3.2. Canada Mycoplasma Testing Market Outlook
 - 6.3.2.1. Market Size & Forecast
 - 6.3.2.1.1. By Value
 - 6.3.2.2. Market Share & Forecast
 - 6.3.2.2.1. By Product
 - 6.3.2.2.2. By Technology
 - 6.3.2.2.3. By Application
 - 6.3.2.2.4. By End User
 - 6.3.3. Mexico Mycoplasma Testing Market Outlook
 - 6.3.3.1. Market Size & Forecast
 - 6.3.3.1.1. By Value
 - 6.3.3.2. Market Share & Forecast
 - 6.3.3.2.1. By Product
 - 6.3.3.2.2. By Technology
 - 6.3.3.2.3. By Application



6.3.3.2.4. By End User

7. EUROPE MYCOPLASMA TESTING MARKET OUTLOOK

- 7.1. Market Size & Forecast
 - 7.1.1. By Value
- 7.2. Market Share & Forecast
 - 7.2.1. By Product
 - 7.2.2. By Technology
 - 7.2.3. By Application
 - 7.2.4. By End User
 - 7.2.5. By Country
- 7.3. Europe: Country Analysis
 - 7.3.1. Germany Mycoplasma Testing Market Outlook
 - 7.3.1.1. Market Size & Forecast
 - 7.3.1.1.1. By Value
 - 7.3.1.2. Market Share & Forecast
 - 7.3.1.2.1. By Product
 - 7.3.1.2.2. By Technology
 - 7.3.1.2.3. By Application
 - 7.3.1.2.4. By End User
 - 7.3.2. United Kingdom Mycoplasma Testing Market Outlook
 - 7.3.2.1. Market Size & Forecast
 - 7.3.2.1.1. By Value
 - 7.3.2.2. Market Share & Forecast
 - 7.3.2.2.1. By Product
 - 7.3.2.2.2. By Technology
 - 7.3.2.2.3. By Application
 - 7.3.2.2.4. By End User
 - 7.3.3. Italy Mycoplasma Testing Market Outlook
 - 7.3.3.1. Market Size & Forecast
 - 7.3.3.1.1. By Value
 - 7.3.3.2. Market Share & Forecast
 - 7.3.3.2.1. By Product
 - 7.3.3.2.2. By Technology
 - 7.3.3.2.3. By Application
 - 7.3.3.2.4. By End User
 - 7.3.4. France Mycoplasma Testing Market Outlook
 - 7.3.4.1. Market Size & Forecast



- 7.3.4.1.1. By Value
- 7.3.4.2. Market Share & Forecast
 - 7.3.4.2.1. By Product
 - 7.3.4.2.2. By Technology
 - 7.3.4.2.3. By Application
- 7.3.4.2.4. By End User
- 7.3.5. Spain Mycoplasma Testing Market Outlook
 - 7.3.5.1. Market Size & Forecast
 - 7.3.5.1.1. By Value
 - 7.3.5.2. Market Share & Forecast
 - 7.3.5.2.1. By Product
 - 7.3.5.2.2. By Technology
 - 7.3.5.2.3. By Application
 - 7.3.5.2.4. By End User

8. ASIA-PACIFIC MYCOPLASMA TESTING MARKET OUTLOOK

- 8.1. Market Size & Forecast
 - 8.1.1. By Value
- 8.2. Market Share & Forecast
 - 8.2.1. By Product
 - 8.2.2. By Technology
 - 8.2.3. By Application
 - 8.2.4. By End User
 - 8.2.5. By Country
- 8.3. Asia-Pacific: Country Analysis
 - 8.3.1. China Mycoplasma Testing Market Outlook
 - 8.3.1.1. Market Size & Forecast
 - 8.3.1.1.1. By Value
 - 8.3.1.2. Market Share & Forecast
 - 8.3.1.2.1. By Product
 - 8.3.1.2.2. By Technology
 - 8.3.1.2.3. By Application
 - 8.3.1.2.4. By End User
 - 8.3.2. India Mycoplasma Testing Market Outlook
 - 8.3.2.1. Market Size & Forecast
 - 8.3.2.1.1. By Value
 - 8.3.2.2. Market Share & Forecast
 - 8.3.2.2.1. By Product



- 8.3.2.2.2. By Technology
- 8.3.2.2.3. By Application
- 8.3.2.2.4. By End User
- 8.3.3. Japan Mycoplasma Testing Market Outlook
 - 8.3.3.1. Market Size & Forecast
 - 8.3.3.1.1. By Value
 - 8.3.3.2. Market Share & Forecast
 - 8.3.3.2.1. By Product
 - 8.3.3.2.2. By Technology
 - 8.3.3.2.3. By Application
 - 8.3.3.2.4. By End User
- 8.3.4. South Korea Mycoplasma Testing Market Outlook
 - 8.3.4.1. Market Size & Forecast
 - 8.3.4.1.1. By Value
 - 8.3.4.2. Market Share & Forecast
 - 8.3.4.2.1. By Product
 - 8.3.4.2.2. By Technology
 - 8.3.4.2.3. By Application
 - 8.3.4.2.4. By End User
- 8.3.5. Australia Mycoplasma Testing Market Outlook
 - 8.3.5.1. Market Size & Forecast
 - 8.3.5.1.1. By Value
 - 8.3.5.2. Market Share & Forecast
 - 8.3.5.2.1. By Product
 - 8.3.5.2.2. By Technology
 - 8.3.5.2.3. By Application
 - 8.3.5.2.4. By End User

9. SOUTH AMERICA MYCOPLASMA TESTING MARKET OUTLOOK

- 9.1. Market Size & Forecast
 - 9.1.1. By Value
- 9.2. Market Share & Forecast
 - 9.2.1. By Product
 - 9.2.2. By Technology
 - 9.2.3. By Application
 - 9.2.4. By End User
 - 9.2.5. By Country
- 9.3. South America: Country Analysis



- 9.3.1. Brazil Mycoplasma Testing Market Outlook
 - 9.3.1.1. Market Size & Forecast
 - 9.3.1.1.1. By Value
 - 9.3.1.2. Market Share & Forecast
 - 9.3.1.2.1. By Product
 - 9.3.1.2.2. By Technology
 - 9.3.1.2.3. By Application
 - 9.3.1.2.4. By End User
- 9.3.2. Argentina Mycoplasma Testing Market Outlook
 - 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value
 - 9.3.2.2. Market Share & Forecast
 - 9.3.2.2.1. By Product
 - 9.3.2.2.2. By Technology
 - 9.3.2.2.3. By Application
 - 9.3.2.2.4. By End User
- 9.3.3. Colombia Mycoplasma Testing Market Outlook
 - 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value
 - 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Product
 - 9.3.3.2.2. By Technology
 - 9.3.3.2.3. By Application
 - 9.3.3.2.4. By End User

10. MIDDLE EAST AND AFRICA MYCOPLASMA TESTING MARKET OUTLOOK

- 10.1. Market Size & Forecast
 - 10.1.1. By Value
- 10.2. Market Share & Forecast
 - 10.2.1. By Product
 - 10.2.2. By Technology
 - 10.2.3. By Application
 - 10.2.4. By End User
 - 10.2.5. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Mycoplasma Testing Market Outlook
 - 10.3.1.1. Market Size & Forecast
 - 10.3.1.1.1. By Value



- 10.3.1.2. Market Share & Forecast
 - 10.3.1.2.1. By Product
 - 10.3.1.2.2. By Technology
 - 10.3.1.2.3. By Application
 - 10.3.1.2.4. By End User
- 10.3.2. Saudi Arabia Mycoplasma Testing Market Outlook
 - 10.3.2.1. Market Size & Forecast
 - 10.3.2.1.1. By Value
 - 10.3.2.2. Market Share & Forecast
 - 10.3.2.2.1. By Product
 - 10.3.2.2.2. By Technology
 - 10.3.2.2.3. By Application
 - 10.3.2.2.4. By End User
- 10.3.3. UAE Mycoplasma Testing Market Outlook
 - 10.3.3.1. Market Size & Forecast
 - 10.3.3.1.1. By Value
 - 10.3.3.2. Market Share & Forecast
 - 10.3.3.2.1. By Product
 - 10.3.3.2.2. By Technology
 - 10.3.3.2.3. By Application
 - 10.3.3.2.4. By End User

11. MARKET DYNAMICS

- 11.1. Drivers
- 11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions

13. GLOBAL MYCOPLASMA TESTING MARKET: SWOT ANALYSIS

14. COMPETITIVE LANDSCAPE

- 14.1. Agilent Technologies Inc
 - 14.1.1. Business Overview



- 14.1.2. Product & Service Offerings
- 14.1.3. Recent Developments
- 14.1.4. Financials (If Listed)
- 14.1.5. Key Personnel
- 14.1.6. SWOT Analysis
- 14.2. ATCC
- 14.3. Bionique Testing Laboratories Inc.
- 14.4. Charles River Laboratories International Inc.
- 14.5. Lonza Group Ltd
- 14.6. Merck KGaA
- 14.7. Bionique Testing Laboratories Inc.
- 14.8. PromoCell GmbH
- 14.9. Thermo Fisher Scientific Inc.
- 14.10.Sartorius AG

15. STRATEGIC RECOMMENDATIONS

16. ABOUT US & DISCLAIMER



I would like to order

Product name: Mycoplasma Testing Market - Global Industry Size, Share, Trends, Opportunity, &

Forecast, Segmented By Product (Instruments, Kits and Reagents), By Technology (PCR, ELISA, Enzymatic Methods, DNA Staining, Other), By Application (Cell Line Testing, Bioproduction Testing, Other), By End-User (Academic Research Institutes, Cell Banks, Contract Research Organizations, Pharmaceutical & Biotechnology Companies, Others),

By Region, Competition, 2020-2030F

Product link: https://marketpublishers.com/r/M3271BF1897DEN.html

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/M3271BF1897DEN.html